$VINC
Vincerx Pharma, Inc.

2024 Q1 Form 10-K Financial Statement

#000119312524081994 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.922M $1.820M $13.64M
YoY Change -35.24% -55.06% -28.05%
% of Gross Profit
Research & Development $4.556M $3.713M $28.97M
YoY Change -56.97% -67.35% -44.45%
% of Gross Profit
Depreciation & Amortization $13.00K $12.00K $52.00K
YoY Change 0.0% -14.29% -3.7%
% of Gross Profit
Operating Expenses $7.478M $5.533M $42.61M
YoY Change -50.47% -64.13% -42.09%
Operating Profit -$7.478M -$42.61M
YoY Change -50.47% -42.09%
Interest Expense $99.00K $198.0K $1.251M
YoY Change -79.55% -53.85% -82.04%
% of Operating Profit
Other Income/Expense, Net -$4.951M $385.0K $1.201M
YoY Change -753.17% -71.5% -85.37%
Pretax Income -$12.43M -$4.950M -$40.16M
YoY Change -13.33% -63.72% -38.57%
Income Tax
% Of Pretax Income
Net Earnings -$12.43M -$4.950M -$40.16M
YoY Change -13.33% -63.72% -38.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58 -$1.89
Diluted Earnings Per Share -$0.58 -$0.23 -$1.89
COMMON SHARES
Basic Shares Outstanding 21.41M 21.38M 21.30K
Diluted Shares Outstanding 21.40K 21.30K

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.110M $12.78M $12.78M
YoY Change -87.15% -75.63% -75.63%
Cash & Equivalents $5.110M $12.78M $12.78M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $760.0K $907.0K $657.0K
YoY Change -77.39% -72.52% -69.2%
Inventory
Prepaid Expenses $700.0K $51.00K
Receivables
Other Receivables
Total Short-Term Assets $7.677M $14.73M $14.73M
YoY Change -82.56% -73.67% -73.67%
LONG-TERM ASSETS
Property, Plant & Equipment $111.0K $2.326M $2.326M
YoY Change -32.32% 1214.12% -28.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $138.0K $1.158M $1.158M
YoY Change -61.02% 1329.63% 1329.63%
Total Long-Term Assets $3.406M $3.484M $3.484M
YoY Change -1.02% 4.88% 4.88%
TOTAL ASSETS
Total Short-Term Assets $7.677M $14.73M $14.73M
Total Long-Term Assets $3.406M $3.484M $3.484M
Total Assets $11.08M $18.22M $18.22M
YoY Change -76.64% -69.27% -69.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.314M $2.497M $2.497M
YoY Change -62.51% -18.53% -18.53%
Accrued Expenses $1.727M $2.917M $2.917M
YoY Change -48.52% -40.75% -50.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.63M $5.605M $5.605M
YoY Change -0.73% -38.78% -38.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K $1.390M $1.390M
YoY Change 0.0% 2680.0% -43.54%
Total Long-Term Liabilities $50.00K $1.390M $1.390M
YoY Change 0.0% 2680.0% -43.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.63M $5.605M $5.605M
Total Long-Term Liabilities $50.00K $1.390M $1.390M
Total Liabilities $11.71M $6.995M $6.995M
YoY Change -9.84% -39.79% -39.79%
SHAREHOLDERS EQUITY
Retained Earnings -$171.5M -$159.1M
YoY Change 26.43% 31.13%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$622.0K $11.22M $11.22M
YoY Change
Total Liabilities & Shareholders Equity $11.08M $18.22M $18.22M
YoY Change -76.64% -69.27% -69.27%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$12.43M -$4.950M -$40.16M
YoY Change -13.33% -63.72% -38.57%
Depreciation, Depletion And Amortization $13.00K $12.00K $52.00K
YoY Change 0.0% -14.29% -3.7%
Cash From Operating Activities -$7.739M -$8.019M -$40.45M
YoY Change -40.89% -41.96% -32.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.750M $41.50M
YoY Change -100.0% -128.21% -202.27%
Cash From Investing Activities $0.00 $5.750M $41.50M
YoY Change -100.0% -128.21% -202.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $114.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 18.00K 114.0K
YoY Change 66.67% -52.63% -59.29%
NET CHANGE
Cash From Operating Activities -7.739M -8.019M -40.45M
Cash From Investing Activities 0.000 5.750M 41.50M
Cash From Financing Activities 5.000K 18.00K 114.0K
Net Change In Cash -7.662M -2.251M 1.161M
YoY Change 6.8% -93.41% -101.16%
FREE CASH FLOW
Cash From Operating Activities -$7.739M -$8.019M -$40.45M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001796129
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39244
CY2023 dei Entity Registrant Name
EntityRegistrantName
Vincerx Pharma, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3197402
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
260 Sheridan Avenue, Suite 400
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
800-6676
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
VINC
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
true
CY2023 dei Document Fin Stmt Restatement Recovery Analysis Flag
DocumentFinStmtRestatementRecoveryAnalysisFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
23000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21413389
CY2023 us-gaap Fair Value Net Derivative Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List
FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#MarketableSecuritiesUnrealizedGainLoss
CY2022 us-gaap Fair Value Net Derivative Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List
FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#MarketableSecuritiesUnrealizedGainLoss
CY2023 us-gaap Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration
GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12782000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11663000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
72000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
70000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
40796000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
134000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1044000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1372000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
784000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1929000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
14733000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
55964000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2201000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3064000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1158000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2023Q4 us-gaap Assets
Assets
18217000
CY2022Q4 us-gaap Assets
Assets
59286000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2497000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4065000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1755000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3923000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1162000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1024000
CY2023Q4 vinc Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
191000
CY2022Q4 vinc Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
144000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5605000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9156000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1340000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2412000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2023Q4 us-gaap Liabilities
Liabilities
6995000
CY2022Q4 us-gaap Liabilities
Liabilities
11618000
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21407510
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21407510
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21242884
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21242884
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170324000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
166647000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159112000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118955000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11222000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47668000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18217000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59286000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13636000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18885000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
28973000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
49837000
CY2023 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022 us-gaap Restructuring Charges
RestructuringCharges
2469000
CY2023 us-gaap Operating Expenses
OperatingExpenses
42609000
CY2022 us-gaap Operating Expenses
OperatingExpenses
71191000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-42609000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-71191000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
47000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6303000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
1251000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
664000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1248000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1240000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2452000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8207000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40157000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62984000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-40000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
69000
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
74000
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-74000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40123000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62989000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21295
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21295
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21029
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21029
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
280000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10056000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
69000
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-74000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62984000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47668000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
114000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3563000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Nature of Business </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 4), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop, use, manufacture, commercialize, sublicense, and distribute a clinical-stage and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s business operations, and those of third parties with whom the Company conducts business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and by economic, business and political events, including inflation and the wars in Ukraine and Israel. The extent to which these factors could continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on the Company’s current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on the Company’s financial position and results of its operations. </div>
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-40000
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
74000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40157000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11222000
CY2023 us-gaap Profit Loss
ProfitLoss
-40157000
CY2022 us-gaap Profit Loss
ProfitLoss
-62984000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3563000
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
10056000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
863000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
885000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
47000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6303000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
630000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
292000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1228000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3158000
CY2023 vinc Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-328000
CY2022 vinc Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-200000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1077000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1372000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1568000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1046000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2168000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
208000
CY2023 vinc Increase Decreasein Lease Liabilities
IncreaseDecreaseinLeaseLiabilities
-934000
CY2022 vinc Increase Decreasein Lease Liabilities
IncreaseDecreaseinLeaseLiabilities
-738000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
50000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40453000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59604000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
11821000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42978000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
53321000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2400000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
41500000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40578000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
114000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
280000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
280000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-40000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1121000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-99831000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11733000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111564000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12854000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11733000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12800000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
166647000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118955000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47668000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59286000
CY2022 us-gaap Operating Expenses
OperatingExpenses
71191000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-71191000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6303000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
664000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1240000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8207000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62984000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62989000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21029
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21029
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">c<div style="letter-spacing: 0px; top: 0px;;display:inline;">onsolidated </div></div>financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experie<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">nce </div>and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company. </div>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3295000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3295000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10133767
CY2023 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1000000
CY2023Q4 vinc Business Combination Share Issue Ratio
BusinessCombinationShareIssueRatio
0.570895
CY2023 vinc Date Of Licence Agreement
DateOfLicenceAgreement
2020-10-07
CY2021Q1 vinc Licence Fee Paid
LicenceFeePaid
5000000
CY2023Q4 vinc Licence Fee Payable
LicenceFeePayable
1000000
CY2022Q4 vinc Licence Fee Payable
LicenceFeePayable
1000000
CY2023Q4 vinc Aggregate Milestone Payments Payable
AggregateMilestonePaymentsPayable
1000000000
CY2022Q2 vinc Percentage Of Employees Reduction
PercentageOfEmployeesReduction
0.33
CY2023Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2500000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
50590000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
40869000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
73000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
40796000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
784000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1929000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
256000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
256000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
131000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
79000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2023 us-gaap Depreciation
Depreciation
52000000
CY2022 us-gaap Depreciation
Depreciation
54000000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
332000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
297000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2502000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2042000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
918000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
923000
CY2023Q4 vinc Accrued Manufacturing Clinical Trial And Related Current
AccruedManufacturingClinicalTrialAndRelatedCurrent
505000
CY2022Q4 vinc Accrued Manufacturing Clinical Trial And Related Current
AccruedManufacturingClinicalTrialAndRelatedCurrent
661000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1755000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3923000
CY2020Q4 vinc Date Of Lease Agreement
DateOfLeaseAgreement
P5Y
CY2020Q4 vinc Date Of Lease Commencement
DateOfLeaseCommencement
2021-01-01
CY2020Q4 us-gaap Lease Cost
LeaseCost
1200000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2500000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2200000
CY2022Q3 vinc Lessee Operating Sub Lease Term Of Contract
LesseeOperatingSubLeaseTermOfContract
P18M
CY2022Q3 vinc Lessee Operating Sub Lease Rent Amount
LesseeOperatingSubLeaseRentAmount
50000000
CY2023 us-gaap Sublease Income
SubleaseIncome
600000
CY2022 us-gaap Sublease Income
SubleaseIncome
300000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1196000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1196000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023 us-gaap Lease Cost
LeaseCost
1196000
CY2022 us-gaap Lease Cost
LeaseCost
1196000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1270000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1048000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1320000
CY2023Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1372000
CY2023Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
28000
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
2720000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
218000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3628000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21407510
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21242884
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3408
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.74
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2509000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.3
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1562000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.89
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4353
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.87
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1131000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.22
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.82
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
262000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.74
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5219
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.74
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
134000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
11.25
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2023Q1 vinc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntrinsicValue
73000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
700000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y7M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.9
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3.3
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.895
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.851
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3563000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10056000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40157000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62984000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21295
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21295
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21029
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21029
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8532000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7715000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-35281000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-58708000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4876000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4276000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40157000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62984000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.007
CY2023 vinc Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Warrants Percent
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfWarrantsPercent
0
CY2022 vinc Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Warrants Percent
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfWarrantsPercent
0.02
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.02
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.007
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.236
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.229
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15475000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9639000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
5235000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
5025000
CY2023Q4 vinc Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
0
CY2022Q4 vinc Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
4198000
CY2023Q4 vinc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
14734000
CY2022Q4 vinc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
7314000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2231000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1635000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
137000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
471000
CY2023Q4 vinc Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
462000
CY2022Q4 vinc Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
722000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38274000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29004000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37748000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28360000
CY2023Q4 vinc Deferred Tax Assets Net Valuation Allowances
DeferredTaxAssetsNetValuationAllowances
526000
CY2022Q4 vinc Deferred Tax Assets Net Valuation Allowances
DeferredTaxAssetsNetValuationAllowances
644000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
526000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
644000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
526000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
644000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12900000
CY2023 vinc Tax Credit Carry Forward Expiration Year
TaxCreditCarryForwardExpirationYear
P2039D
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
518000
CY2022 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-164000
CY2022 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromCurrentPeriodTaxPositions
625000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
979000
CY2023 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
0
CY2023 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromCurrentPeriodTaxPositions
259000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1238000
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001193125-24-081994-index-headers.html Edgar Link pending
0001193125-24-081994-index.html Edgar Link pending
0001193125-24-081994.txt Edgar Link pending
0001193125-24-081994-xbrl.zip Edgar Link pending
d739497d10k.htm Edgar Link pending
d739497dex211.htm Edgar Link pending
d739497dex231.htm Edgar Link pending
d739497dex311.htm Edgar Link pending
d739497dex312.htm Edgar Link pending
d739497dex321.htm Edgar Link pending
d739497dex322.htm Edgar Link pending
d739497dex971.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g739497g02c90.jpg Edgar Link pending
g739497g18j79.jpg Edgar Link pending
g739497g28l72.jpg Edgar Link pending
g739497g44r00.jpg Edgar Link pending
g739497g48u85.jpg Edgar Link pending
g739497g58u95.jpg Edgar Link pending
g739497g60m33.jpg Edgar Link pending
g739497g61b65.jpg Edgar Link pending
g739497g67a65.jpg Edgar Link pending
g739497g74b32.jpg Edgar Link pending
g739497g74z96.jpg Edgar Link pending
g739497g78d87.jpg Edgar Link pending
g739497g82i65.jpg Edgar Link pending
g739497g93f68.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d739497d10k_htm.xml Edgar Link completed
g739497g93n77.jpg Edgar Link pending
g739497g98w03.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vinc-20231231.xsd Edgar Link pending
vinc-20231231_def.xml Edgar Link unprocessable
vinc-20231231_pre.xml Edgar Link unprocessable
vinc-20231231_cal.xml Edgar Link unprocessable
vinc-20231231_lab.xml Edgar Link unprocessable